Indivior Says FDA Petition Didn't Delay Generic Suboxone
Indivior PLC told a Pennsylvania federal judge on Wednesday that its U.S. Food and Drug Administration petition did not delay the approval of generic versions of the opiate addiction treatment Suboxone,...To view the full article, register now.
Already a subscriber? Click here to view full article